Eversana taps Cornerstone’s research services, expands insights offering

By Vassia Barba contact

- Last updated on GMT

(Image: Getty/Chainarong Prasertthai)
(Image: Getty/Chainarong Prasertthai)

Related tags: Eversana, Data, Data management, acquisition

Eversana acquires Cornerstone Research Group with an aim to expand its portfolio of Health Economics and Outcomes Research (HEOR).

Canada-based Cornerstone Research Group is a provider of Health Economics and Outcomes Research (HEOR) services, working with pharmaceutical and medical device companies.

Through the acquisition, the financial details of which were not disclosed, Eversana aims to add these capabilities in its portfolio on a global scale.

More specifically, upon completion of the transaction, the acquiring company will add a range of services in its offering, including economic modeling, evidence synthesis, value communication, and reimbursement strategies across all stages of drug development.

The transaction is expected to close in the coming quarter, with Cornerstone’s executives, Chris Cameron, Daniel Grima, and Melissa Thompson being appointed into leadership roles at Eversana.

Jim Lang, CEO of Eversana, told us that the addition of Cornerstone “will strengthen the company’s HEOR capabilities, further solidify depth and breadth of expertise,” ​as well as help Eversana expand its global footprint.

According to Lang, Cornerstone’s team consists of “experts in reimbursement strategy, evidence synthesis, economic modeling, data analytics and value communication.” 

The acquisition will allow Eversana to answer market demands coming from pharmaceutical companies that “face strong pressures to quickly assess and quantify both the direct and indirect value of their in-market products and development pipeline,”​ the CEO said in a statement.

“By adding a strong health economics and outcomes capability to our integrated commercial platform, we can now conceptualize, deliver and measure value at every stage of the product lifecycle from clinical trials to ongoing patient adherence,” ​Lang added.

“The need for evidence-based research has never been greater than in today’s pharmaceutical industry,” ​Melissa Thompson commented on her side.

Continuous expansion

The company has been taking significant steps to boost its growth over the past year, with the most recent being the opening of its fourth distribution center in the US​, announced earlier in October, with an aim to answer an increased demand in logistics services, according to Danny Williams, president of Channel Management at Eversana.

Williams also told us then that the company has seen an increase in demand for storage and distribution of temperature-sensitive products, a market need that it expects to address through the recently-established partnership​ with the cold-chain logistics services provider, Cryoport.

Earlier this year, Eversana also announced an expansion of its footprint in Asia, with the opening of four new offices​ in China, Japan, Singapore, and India.

Related news

Show more

Related products

show more

GLP Tissue Cross Reactivity Testing

GLP Tissue Cross Reactivity Testing

Precision for Medicine | 11-Oct-2021 | Product Brochure

Precision for Medicine's unique combination of research services and tissue procurement capabilities form the pillars of our GLP Tissue Cross Reactivity...

Automating clinical trials for success

Automating clinical trials for success

Formedix | 06-Oct-2021 | Technical / White Paper

This article gives gives a brief overview of why automation is absolutely essential for clinical trial success.

Related suppliers

Follow us


View more